GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into ...
Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, ...
Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal ...
The new fiscal year is already two days into its own ledger. On 2 October 2026, FDA issued a letter to Hanlim Pharm in Yongin ...
New CAS Connections integration combines over 150 years of curated scientific knowledge with CAS Newton’s agentic AI ...
NeuroXT Inc., a medical device manufacturer, announced that NEXT-Cue, its AI-based Software as a Medical Device (SaMD) ...
New Phase II/III study will evaluate ivonescimab plus chemotherapy against existing immunotherapy-based treatments, building ...
Median 234 days from first CRO contact to site activation, range 74 to 657; median ethics approval 48 days, median governance ...
Medical device makers went digital to stay audit-ready. Yet their device history records are still being stitched together by ...
UK Collaboration to Explore Digital-First Screening for Early Detection of High Blood Pressure, Expanding Preventive ...
The IMPACT31 trial will enrol 90 high-risk liver cancer patients across the US and Asia-Pacific to evaluate GNOS-PV02 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results